Research Analysts Set Expectations for Absci Q3 Earnings

Key Points

• HC Wainwright has lowered their Q3 2025 EPS estimate for Absci Corporation from ($0.06) to ($0.20), reflecting a negative outlook for the company's earnings.
• Absci's stock has seen a recent downgrade from various analysts, with Needham reducing its target price from $9.00 to $8.00, while Morgan Stanley also cut their target to $6.40.
• Insider Andreas Busch purchased 50,000 shares of Absci, indicating confidence in the stock despite its current challenges.

Absci Corporation (NASDAQ:ABSI - Free Report) - Investment analysts at HC Wainwright decreased their Q3 2025 earnings per share (EPS) estimates for shares of Absci in a report issued on Wednesday, August 13th. HC Wainwright analyst S. Ramakanth now expects that the company will earn ($0.20) per share for the quarter, down from their prior forecast of ($0.06). The consensus estimate for Absci's current full-year earnings is ($0.89) per share. HC Wainwright also issued estimates for Absci's Q4 2025 earnings at ($0.20) EPS, FY2025 earnings at ($0.85) EPS, Q1 2026 earnings at ($0.14) EPS, Q2 2026 earnings at ($0.14) EPS, Q3 2026 earnings at ($0.06) EPS, FY2026 earnings at ($0.47) EPS, FY2027 earnings at ($0.17) EPS, FY2028 earnings at $0.22 EPS and FY2029 earnings at $0.19 EPS.

A number of other equities analysts also recently weighed in on the company. Morgan Stanley dropped their target price on Absci from $6.40 to $5.89 and set an "overweight" rating on the stock in a report on Monday. Needham & Company LLC dropped their target price on Absci from $9.00 to $8.00 and set a "buy" rating on the stock in a report on Wednesday, August 13th. Finally, Wall Street Zen downgraded Absci from a "hold" rating to a "strong sell" rating in a report on Saturday. Five research analysts have rated the stock with a Buy rating, According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $7.98.

Absci Stock Down 1.9%

Shares of ABSI traded down $0.05 during trading hours on Friday, reaching $2.57. The company's stock had a trading volume of 3,670,836 shares, compared to its average volume of 4,754,887. The firm has a market cap of $384.27 million, a price-to-earnings ratio of -2.73 and a beta of 2.02. Absci has a 1-year low of $2.01 and a 1-year high of $6.33. The company has a 50 day moving average of $2.87 and a two-hundred day moving average of $3.14.

Absci (NASDAQ:ABSI - Get Free Report) last issued its earnings results on Tuesday, August 12th. The company reported ($0.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.05). The business had revenue of $0.59 million during the quarter, compared to analyst estimates of $1.39 million. Absci had a negative net margin of 2,737.94% and a negative return on equity of 60.21%.

Hedge Funds Weigh In On Absci

A number of hedge funds have recently added to or reduced their stakes in the company. ARK Investment Management LLC grew its holdings in Absci by 32.5% during the first quarter. ARK Investment Management LLC now owns 10,955,089 shares of the company's stock valued at $27,497,000 after purchasing an additional 2,689,153 shares during the last quarter. Massachusetts Financial Services Co. MA acquired a new position in Absci during the first quarter valued at approximately $5,792,000. Marshall Wace LLP acquired a new position in Absci during the second quarter valued at approximately $1,575,000. Nuveen LLC acquired a new position in Absci during the first quarter valued at approximately $1,251,000. Finally, Geode Capital Management LLC grew its holdings in Absci by 22.5% during the second quarter. Geode Capital Management LLC now owns 2,445,450 shares of the company's stock valued at $6,286,000 after purchasing an additional 448,984 shares during the last quarter. Institutional investors and hedge funds own 52.05% of the company's stock.

Insider Buying and Selling

In other news, insider Andreas Busch acquired 50,000 shares of the company's stock in a transaction that occurred on Monday, July 28th. The shares were purchased at an average price of $3.04 per share, for a total transaction of $152,000.00. Following the completion of the acquisition, the insider owned 327,264 shares of the company's stock, valued at approximately $994,882.56. This represents a 18.03% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 10.49% of the company's stock.

Absci Company Profile

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit.